AIMS/HYPOTHESIS: The role of the intestine in the pathogenesis of metabolic diseases is gaining much attention. We therefore sought to validate, using an animal model, the use of positron emission tomography (PET) in the estimation of intestinal glucose uptake (GU), and thereafter to test whether intestinal insulin-stimulated GU is altered in morbidly obese compared with healthy human participants. METHODS: In the validation study, pigs were imaged using [(18)F]fluorodeoxyglucose ([(18)F]FDG) and the image-derived data were compared with corresponding ex vivo measurements in tissue samples and with arterial-venous differences in glucose and [(18)F]FDG levels. In the clinical study, GU was measured in different regions of the intestine in lean (n = 8) and morbidly obese (n = 8) humans at baseline and during euglycaemic hyperinsulinaemia. RESULTS: PET- and ex vivo-derived intestinal values were strongly correlated and most of the fluorine-18-derived radioactivity was accumulated in the mucosal layer of the gut wall. In the gut wall of pigs, insulin promoted GU as determined by PET, the arterial-venous balance or autoradiography. In lean human participants, insulin increased GU from the circulation in the duodenum (from 1.3 ± 0.6 to 3.1 ± 1.1 μmol [100 g](-1) min(-1), p < 0.05) and in the jejunum (from 1.1 ± 0.7 to 3.0 ± 1.5 μmol [100 g](-1) min(-1), p < 0.05). Obese participants failed to show any increase in insulin-stimulated GU compared with fasting values (NS). CONCLUSIONS/ INTERPRETATION: Intestinal GU can be quantified in vivo by [(18)F]FDG PET. Intestinal insulin resistance occurs in obesity before the deterioration of systemic glucose tolerance.
AIMS/HYPOTHESIS: The role of the intestine in the pathogenesis of metabolic diseases is gaining much attention. We therefore sought to validate, using an animal model, the use of positron emission tomography (PET) in the estimation of intestinal glucose uptake (GU), and thereafter to test whether intestinal insulin-stimulated GU is altered in morbidly obese compared with healthy humanparticipants. METHODS: In the validation study, pigs were imaged using [(18)F]fluorodeoxyglucose ([(18)F]FDG) and the image-derived data were compared with corresponding ex vivo measurements in tissue samples and with arterial-venous differences in glucose and [(18)F]FDG levels. In the clinical study, GU was measured in different regions of the intestine in lean (n = 8) and morbidly obese (n = 8) humans at baseline and during euglycaemic hyperinsulinaemia. RESULTS: PET- and ex vivo-derived intestinal values were strongly correlated and most of the fluorine-18-derived radioactivity was accumulated in the mucosal layer of the gut wall. In the gut wall of pigs, insulin promoted GU as determined by PET, the arterial-venous balance or autoradiography. In lean humanparticipants, insulin increased GU from the circulation in the duodenum (from 1.3 ± 0.6 to 3.1 ± 1.1 μmol [100 g](-1) min(-1), p < 0.05) and in the jejunum (from 1.1 ± 0.7 to 3.0 ± 1.5 μmol [100 g](-1) min(-1), p < 0.05). Obeseparticipants failed to show any increase in insulin-stimulated GU compared with fasting values (NS). CONCLUSIONS/ INTERPRETATION: Intestinal GU can be quantified in vivo by [(18)F]FDG PET. Intestinal insulin resistance occurs in obesity before the deterioration of systemic glucose tolerance.
Authors: K A Virtanen; P Peltoniemi; P Marjamäki; M Asola; L Strindberg; R Parkkola; R Huupponen; J Knuuti; P Lönnroth; P Nuutila Journal: Diabetologia Date: 2001-12 Impact factor: 10.122
Authors: Shengli Ding; Michael M Chi; Brooks P Scull; Rachael Rigby; Nicole M J Schwerbrock; Scott Magness; Christian Jobin; Pauline K Lund Journal: PLoS One Date: 2010-08-16 Impact factor: 3.240
Authors: Henning Hvid; Jonas Kildegaard; Kim Kristensen; Trine Porsgaard; Mikkel S Jørgensen; Borja Ballarín-González; Jonas Ahnfelt-Rønne; Bo F Hansen; Erica Nishimura Journal: J Diabetes Sci Technol Date: 2019-06-12
Authors: Han-Chow E Koh; Stephan van Vliet; Gretchen A Meyer; Richard Laforest; Robert J Gropler; Samuel Klein; Bettina Mittendorfer Journal: Diabetologia Date: 2021-01-29 Impact factor: 10.122
Authors: Jaakko Mäkinen; Jarna C Hannukainen; Anna Karmi; Heidi M Immonen; Minna Soinio; Lassi Nelimarkka; Nina Savisto; Mika Helmiö; Jari Ovaska; Paulina Salminen; Patricia Iozzo; Pirjo Nuutila Journal: Diabetologia Date: 2015-01-29 Impact factor: 10.122
Authors: Viktoria V Мokrozub; Liudmyla M Lazarenko; Liubov M Sichel; Lidia P Babenko; Petro M Lytvyn; Olga M Demchenko; Yulia O Melnichenko; Nadiya V Boyko; Bruno Biavati; Diana DiGioia; Rostyslav V Bubnov; Mykola Ya Spivak Journal: EPMA J Date: 2015-06-19 Impact factor: 6.543
Authors: Aino Latva-Rasku; Miikka-Juhani Honka; Alena Stančáková; Heikki A Koistinen; Johanna Kuusisto; Li Guan; Alisa K Manning; Heather Stringham; Anna L Gloyn; Cecilia M Lindgren; Francis S Collins; Karen L Mohlke; Laura J Scott; Tomi Karjalainen; Lauri Nummenmaa; Michael Boehnke; Pirjo Nuutila; Markku Laakso Journal: Diabetes Date: 2017-11-15 Impact factor: 9.461
Authors: Kumail K Motiani; Anna M Savolainen; Jari-Joonas Eskelinen; Jussi Toivanen; Tamiko Ishizu; Minna Yli-Karjanmaa; Kirsi A Virtanen; Riitta Parkkola; Jukka Kapanen; Tove J Grönroos; Merja Haaparanta-Solin; Olof Solin; Nina Savisto; Markku Ahotupa; Eliisa Löyttyniemi; Juhani Knuuti; Pirjo Nuutila; Kari K Kalliokoski; Jarna C Hannukainen Journal: J Appl Physiol (1985) Date: 2017-02-09
Authors: Han-Chow E Koh; Stephan van Vliet; Terri A Pietka; Gretchen A Meyer; Babak Razani; Richard Laforest; Robert J Gropler; Bettina Mittendorfer Journal: Diabetes Date: 2021-07-15 Impact factor: 9.337